Sensex edges lower; lenders, drugmakers fall

Image
Reuters
Last Updated : Mar 21 2017 | 1:22 PM IST

By Aby Jose Koilparambil

REUTERS - Indian shares fell for a second consecutive session on Tuesday, as lenders such as Axis Bank were hit by a Morgan Stanley downgrade while worries of regulatory action from the U.S. Food and Drug Administration triggered selling in drugmakers.

Analysts expect a period of consolidation ahead as investors focus on individual stock movements as they wait for the earnings season to start in mid-April.

"The markets have been trending up since December. I think this week market may just cool off," said Sacchidanand Uttekar, equity technical analyst at Motilal Oswal Securities.

"There will be profit booking in major index-contributing stocks including Reliance Industries."

The broader Nifty had closed at a record high last week.

The index was down 0.29 percent at 9,100.45 by 0713 GMT, while the benchmark Sensex was 0.37 percent lower at 29,408.59.

Banks were among the biggest losers after Morgan Stanley downgraded a slew of large Indian lenders, citing expectation of weak earnings.

Axis Bank fell 2.72 percent and ICICI Bank lost 0.80 percent.

Drug makers slumped on worries of regulatory action from the U.S. Food and Drug Administration.

Divi's Laboratories Ltd fell as much as 20 percent following an import alert issued by the USFDA on products manufactured at its Visakhapatnam unit

Shares of Avenue Supermarts Ltd more than doubled in value on their trading debut. Analysts expect strong potential for its supermarkets and retail stores.

Bharti Infratel was up more than a percent after Nettle Infra Investments bought about 21.63 percent stake in co from promoter Bharti Airtel.

(Reporting by Aby Jose Koilparambil in Bengaluru; Editing by Vyas Mohan)

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 21 2017 | 1:07 PM IST

Next Story